Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALBO NASDAQ:KALV NASDAQ:KDNY NASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALBOAlbireo Pharma$44.15$44.17$16.02▼$45.23$913.91M1.03704,539 shs1.24 million shsKALVKalVista Pharmaceuticals$13.17-5.1%$13.97$7.30▼$17.28$701.26M-0.1982,270 shs1.79 million shsKDNYChinook Therapeutics$40.39$39.86$18.34▼$40.51$2.90B0.341.19 million shsN/AXENEXenon Pharmaceuticals$36.95-2.1%$35.36$26.74▼$46.00$2.91B1.17611,755 shs1.03 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALBOAlbireo Pharma0.00%0.00%0.00%0.00%0.00%KALVKalVista Pharmaceuticals-5.12%-6.00%+2.01%+8.40%+23.20%KDNYChinook Therapeutics0.00%0.00%0.00%0.00%0.00%XENEXenon Pharmaceuticals-2.15%+2.04%-1.83%+15.29%-7.83%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALBOAlbireo Pharma$44.15$44.17$16.02▼$45.23$913.91M1.03704,539 shs1.24 million shsKALVKalVista Pharmaceuticals$13.17-5.1%$13.97$7.30▼$17.28$701.26M-0.1982,270 shs1.79 million shsKDNYChinook Therapeutics$40.39$39.86$18.34▼$40.51$2.90B0.341.19 million shsN/AXENEXenon Pharmaceuticals$36.95-2.1%$35.36$26.74▼$46.00$2.91B1.17611,755 shs1.03 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALBOAlbireo Pharma0.00%0.00%0.00%0.00%0.00%KALVKalVista Pharmaceuticals-5.12%-6.00%+2.01%+8.40%+23.20%KDNYChinook Therapeutics0.00%0.00%0.00%0.00%0.00%XENEXenon Pharmaceuticals-2.15%+2.04%-1.83%+15.29%-7.83%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALBOAlbireo Pharma 0.00N/AN/AN/AKALVKalVista Pharmaceuticals 3.11Buy$26.43100.67% UpsideKDNYChinook Therapeutics 0.00N/AN/AN/AXENEXenon Pharmaceuticals 3.00Buy$53.3044.25% UpsideCurrent Analyst Ratings BreakdownLatest ALBO, XENE, KDNY, and KALV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$28.009/12/2025KALVKalVista PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$27.00 ➝ $28.009/3/2025XENEXenon PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$48.009/2/2025XENEXenon PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$55.008/12/2025XENEXenon PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$55.008/12/2025XENEXenon PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$57.00 ➝ $55.008/12/2025XENEXenon PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$42.00 ➝ $43.007/8/2025KALVKalVista PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$19.00 ➝ $27.007/8/2025KALVKalVista PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $27.007/7/2025KALVKalVista PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$18.00 ➝ $20.00(Data available from 9/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALBOAlbireo Pharma$40.58M22.52N/AN/A$9.11 per share4.85KALVKalVista PharmaceuticalsN/AN/AN/AN/A$0.81 per shareN/AKDNYChinook Therapeutics$6.13M473.15N/AN/A$6.91 per share5.85XENEXenon Pharmaceuticals$9.43M302.14N/AN/A$9.90 per share3.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALBOAlbireo Pharma-$34.03M-$6.72N/AN/AN/A-228.51%-97.13%-46.89%N/AKALVKalVista Pharmaceuticals-$183.44M-$3.94N/AN/AN/AN/A-195.62%-89.96%12/4/2025 (Estimated)KDNYChinook Therapeutics-$187.87M-$3.52N/AN/AN/A-4,199.93%-58.28%-44.72%N/AXENEXenon Pharmaceuticals-$234.33M-$3.55N/AN/AN/AN/A-38.50%-36.47%11/11/2025 (Estimated)Latest ALBO, XENE, KDNY, and KALV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/11/2025Q1 2026KALVKalVista Pharmaceuticals-$0.91-$1.12-$0.21-$1.12$1.97 million$1.43 million8/11/2025Q2 2025XENEXenon Pharmaceuticals-$1.03-$1.07-$0.04-$1.07N/AN/A7/10/2025Q4 2025KALVKalVista Pharmaceuticals-$0.83-$3.69-$2.86-$0.99$4.20 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALBOAlbireo PharmaN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/AKDNYChinook TherapeuticsN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALBOAlbireo PharmaN/A6.326.23KALVKalVista PharmaceuticalsN/A5.375.37KDNYChinook TherapeuticsN/A5.825.82XENEXenon PharmaceuticalsN/A15.1415.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALBOAlbireo Pharma94.25%KALVKalVista PharmaceuticalsN/AKDNYChinook Therapeutics95.15%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipALBOAlbireo Pharma6.90%KALVKalVista Pharmaceuticals4.30%KDNYChinook Therapeutics16.79%XENEXenon Pharmaceuticals4.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALBOAlbireo Pharma13020.70 million19.27 millionOptionableKALVKalVista Pharmaceuticals10050.52 million48.35 millionOptionableKDNYChinook Therapeutics21471.81 million59.75 millionOptionableXENEXenon Pharmaceuticals21077.11 million73.97 millionOptionableALBO, XENE, KDNY, and KALV HeadlinesRecent News About These CompaniesHarbor Capital Advisors Inc. Sells 26,555 Shares of Xenon Pharmaceuticals Inc. $XENESeptember 19 at 3:36 AM | marketbeat.comInvestors Purchase High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)September 18 at 2:55 AM | marketbeat.comWhy Is Xenon Pharmaceuticals (XENE) Up 4.2% Since Last Earnings Report?September 10, 2025 | zacks.comAlliancebernstein L.P. Lowers Holdings in Xenon Pharmaceuticals Inc. $XENESeptember 9, 2025 | marketbeat.comParkman Healthcare Partners LLC Decreases Stake in Xenon Pharmaceuticals Inc. $XENESeptember 8, 2025 | marketbeat.comAlyeska Investment Group L.P. Purchases 78,390 Shares of Xenon Pharmaceuticals Inc. $XENESeptember 7, 2025 | marketbeat.comWells Fargo & Company Reiterates Overweight Rating for Xenon Pharmaceuticals (NASDAQ:XENE)September 5, 2025 | marketbeat.comAlly Bridge Group NY LLC Trims Position in Xenon Pharmaceuticals Inc. $XENESeptember 5, 2025 | marketbeat.comXenon Pharmaceuticals Inc. $XENE Shares Acquired by Adage Capital Partners GP L.L.C.September 5, 2025 | marketbeat.comInvestors Buy High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)September 5, 2025 | marketbeat.comXenon Pharmaceuticals' (XENE) Outperform Rating Reiterated at Royal Bank Of CanadaSeptember 4, 2025 | marketbeat.comADAR1 Capital Management LLC Has $4.28 Million Holdings in Xenon Pharmaceuticals Inc. $XENESeptember 4, 2025 | marketbeat.comFirst Light Asset Management LLC Sells 532,676 Shares of Xenon Pharmaceuticals Inc. $XENESeptember 4, 2025 | marketbeat.comXenon Pharmaceuticals Inc. $XENE is Vestal Point Capital LP's 9th Largest PositionSeptember 4, 2025 | marketbeat.comBirchview Capital LP Has $705,000 Stake in Xenon Pharmaceuticals Inc. $XENESeptember 4, 2025 | marketbeat.comMPM Bioimpact LLC Raises Stock Holdings in Xenon Pharmaceuticals Inc. $XENESeptember 4, 2025 | marketbeat.comBaker BROS. Advisors LP Sells 646,271 Shares of Xenon Pharmaceuticals Inc. $XENESeptember 4, 2025 | marketbeat.comXenon Pharmaceuticals assumed with an Overweight at Wells FargoSeptember 3, 2025 | msn.comXenon Pharmaceuticals Inc. $XENE Shares Sold by Braidwell LPSeptember 3, 2025 | marketbeat.comDriehaus Capital Management LLC Raises Stock Position in Xenon Pharmaceuticals Inc. $XENEAugust 31, 2025 | marketbeat.comSiren L.L.C. Sells 11,008 Shares of Xenon Pharmaceuticals Inc. $XENEAugust 31, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALBO, XENE, KDNY, and KALV Company DescriptionsAlbireo Pharma NASDAQ:ALBOAlbireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.KalVista Pharmaceuticals NASDAQ:KALV$13.17 -0.71 (-5.12%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$13.14 -0.03 (-0.23%) As of 09/19/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.Chinook Therapeutics NASDAQ:KDNYChinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.Xenon Pharmaceuticals NASDAQ:XENE$36.95 -0.81 (-2.15%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$36.94 -0.01 (-0.01%) As of 09/19/2025 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Azure Leads While AI Excitement Fuels Microsoft Stock The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Workday Rising… To Fresh Record High Stock Prices 3 Reasons Amazon Could Be at an All-Time High by October Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
